Labcorp appoints Dr. Paul Rothman to Board of Directors

LABCORP HOLDINGS INC.

Dr. Rothman appointed as independent director effective June 6, 2023, expanding board to 12 members (11 independent).
Rothman recently retired as CEO of Johns Hopkins Medicine, a $9B academic medical enterprise, after a decade of service.
He is a rheumatologist and molecular immunologist with leadership roles at Columbia University and University of Iowa.
Rothman currently serves on the boards of Merck & Co. and King Faisal Specialist Hospital and Research Center.
Compensation follows Labcorp's standard director compensation program as described in the March 2023 proxy statement.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Paul B. Rothman

member of the Board

LH · LABCORP HOLDINGS INC.

Effective: 2023-06-06
Filed: June 7, 2023, 7:59 PM ET

Laboratory Corporation of America Holdings (“Labcorp”) today announced that on June 5, 2023, Labcorp’s Board of Directors (the “Board”) appointed Paul B. Rothman as a member of the Board, effective June 6, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Paul B. Rothman was appointed as member of the Board at LABCORP HOLDINGS INC..

Action: appointed
Role: member of the Board

Exact text from the filing

Laboratory Corporation of America Holdings (“Labcorp”) today announced that on June 5, 2023, Labcorp’s Board of Directors (the “Board”) appointed Paul B. Rothman as a member of the Board, effective June 6, 2023.

View on SEC.gov

LABCORP HOLDINGS INC. filing history →

Source: SEC EDGAR

accession 0000920148-23-000040

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.